Affiliation: New England Biolabs
- The Wolbachia genome of Brugia malayi: endosymbiont evolution within a human pathogenic nematodeJeremy Foster
Molecular Parasitology Division, New England Biolabs, Beverly, Massachusetts, USA
PLoS Biol 3:e121. 2005..Analysis of this first sequenced endosymbiont genome from a filarial nematode provides insight into endosymbiont evolution and additionally provides new potential targets for elimination of cutaneous and lymphatic human filarial disease...
- Diversifying selection and host adaptation in two endosymbiont genomesJeremy C Brownlie
School of Integrative Biology, University of Queensland, Brisbane, QLD, Australia
BMC Evol Biol 7:68. 2007..The goal of the study was to identify likely molecular mechanisms of the symbiosis and to understand the nature of the diverse association across different hosts...
- The bacterial catalase from filarial DNA preparations derives from common pseudomonad contaminants and not from Wolbachia endosymbiontsJeremy Foster
New England Biolabs, Beverly, MA 01915, USA
Parasitol Res 94:141-6. 2004..Contamination of filarial DNA with bacterial sequences other than Wolbachia can complicate studies of the role of these symbionts in filarial biology...
- Sequencing and analysis of a 63 kb bacterial artificial chromosome insert from the Wolbachia endosymbiont of the human filarial parasite Brugia malayiJennifer Ware
New England Biolabs, Inc, 32 Tozer Road, Beverly, MA 01915, USA
Int J Parasitol 32:159-66. 2002..malayi host. This will also lead to a better understanding of the interactions between the endosymbiont and its host and will offer novel approaches and drug targets for elimination of filarial disease...
- The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug targetBo Wu
Division of Molecular Parasitology, New England Biolabs, Ipswich, Massachusetts, United States of America
PLoS Negl Trop Dis 3:e475. 2009..Human trials have confirmed this approach, although the length of treatments, high doses required and medical counter-indications for young children and pregnant women warrant the identification of additional anti-Wolbachia drugs...